An interventional study of CCTA-based CABG and CAG-based CABG in Coronary Artery Disease, Coronary Artery Bypass Grafting and Coronary Computed Tomography Angiography, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Ruijin Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Coronary Artery Disease by Ruijin Hospital — 10 open to participants now, 11 under way, none of them phase 3. Coronary Artery Disease · Ruijin Hospital.
Among the 15 studies in Coronary Artery Disease by Ruijin Hospital, this one is one of 3 that started in 2026, is one of 2 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 15th registered.
4,862 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →10 of the 15 studies in Coronary Artery Disease by Ruijin Hospital are open now, in 1 country. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18–80
Ruijin Hospital · Sites in China
Ages 18–80
Ruijin Hospital · Sites in China
Ages 18–80
By country, each count listing its studies:
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 826 is above the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.
Median enrollment 792 across the 3 interventional studies, 460 across the 12 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ruijin Hospital is the lead sponsor of 679 studies on the registry; 387 are open to participants now.
2 of the studies in Coronary Artery Disease by Ruijin Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06137521Ruijin HospitalRisk Factors and Outcomes in Coronary Chronic Total Occlusion | 2026-12-31 |
| NCT06794684Ruijin HospitalPRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging tEchniques | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Coronary Artery Disease by Ruijin Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to find out if using a non-invasive heart scan (called coronary computed tomography angiography, or CCTA) to plan coronary artery bypass grafting (CABG) works as well as the standard invasive approach (called coronary angiography, or CAG) for people with blocked heart arteries.
The main questions it aims to answer are:
Do people who have surgery planned with the non-invasive heart scan have similar health outcomes at 1 year as those who have surgery planned with the standard invasive approach? How does the non-invasive approach compare in terms of heart attacks, strokes, unplanned repeat procedures, and longer hospital stays? Researchers will compare two groups of participants. One group will have their surgery planned using only the CCTA . The other group will have their surgery planned using only the CAG. Both groups will undergo the CABG per local protocol.
Participants will:
Be randomly assigned (like flipping a coin) to one of the two planning approaches Undergo CABG as scheduled Return for follow-up visits at sugery days, 7 days, 1 month, 6 months, and 1 year after surgery Have a follow-up CCTA scan at 7 days and 1 year to check if the new bypass grafts are working well
An internal pilot trial integrated with the main trial will enroll 80 participants to assess protocol adherence, recruitment efficiency, follow-up completion rates, and the overall feasibility of trial procedures. Provided that no major protocol amendments are made upon completion of the pilot phase, these 80 participants will be included in the primary analysis of the main trial.
The primary feasibility outcome include: initial screening success rate; informed consent completion rate; randomization completion rate following informed consent; recruitment rate(monthly recruitment number per site); rate of CABG planned and executed based solely on CTA; substantial concordance rate between planned and actually executed revascularization; 7-day postoperative CCTA follow-up completion rate, and 30-day clinical follow-up completion rate; and to explore the 7 day graft failure (Modified FitzGibbon grade B, S, or O), 30-day operative mortality and morbidity as clinical outcome.
The criteria were revised on the registry on Oct 27, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known allergy to iodinated contrast media; Active hyperthyroidism or uncontrolled thyroid disease; Estimated (eGFR) \< 30 mL/min/1.73 m²; Atrial fibrillation with rapid ventricular response or severe arrhythmias not amenable to rate control;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: CCTA-based CABG
Procedure: CAG-based CABG
Surgical planning based solely on CCTA-derived data, including diameter stenosis (DS), area stenosis (AS), CT-derived fractional flow reserve (CT-FFR), LV:RV perfusion index, plaque characterization, 3D reconstruction of target vessels, and collateral circulation of chronic total occlusions (CTO) and so on. CCTA performed using photon-counting CT or conventional CT (≥64-slice, preferably ≥256-slice), following a standardized acquisition protocol. Images are transferred to an independent core laboratory for quantitative analysis and standardized reporting. The operating surgeon will not have access to CAG.
Surgical planning following standard practice using invasive coronary angiography(CAG). Angiograms obtained using a flat-panel detector system with standardized projections. The results of CAG are interpreted by the operating surgeon.The operating surgeon will not have access to CCTA.
1-year incidence of 5-Point Major Adverse Cardiovascular Events (5P-MACE)
The 5P-MACE was defined as a composite of all-cause death, myocardial infarction, stroke, unplanned revascularization, and CABG-related or cardiovascular-related prolonged postoperative length of stay (PLOS) or rehospitalization.
Time frame: Within 1 year post-CABG
1-year incidence of all-cause death
Time frame: Within 1 year post-CABG
1-year incidence of CV death
Time frame: within 1 year post-CABG
1-year incidence of MI
Time frame: Within 1 year post-CABG
1-year incidence of stroke
Time frame: Within 1 year post-CABG
1-year incidence of unplanned revascularization
Time frame: Within 1 year post-CABG
1-year incidence of CABG-related or CV-related prolonged PLOS or rehospitalization.
Time frame: Within 1 year post-CABG
30-day incidence of the operative mortality and morbidity
The operative mortality and morbidity was defined as a composite of all-cause death, myocardial infarction, stroke, unplanned revascularization, cardiac arrest, reoperation, prolonged ventilation, deep sternal wound infection, pacemaker implantation, major gastrointestinal bleeding, and new dialysis .
Time frame: Within 30 days post-CABG
7-day graft failure rate
Graft failure defined as modified FitzGibbon grade B, S, or O, assessed by CCTA.
Time frame: At 7 day post-CABG
1-year graft failure rate
Graft failure defined as modified FitzGibbon grade B, S, or O, assessed by CCTA.
Time frame: At 1 year post-CABG
Other serious adverse events (SAE)
Important medical events that impact subjects' daily life or health and require appropriate intervention, but are not part of the primary or secondary outcome definitions above
Time frame: Within 1 year post-CABG
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Aug 2029, 36 months after the start.
Of 753 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 36 months is close to that.
Counting every sponsor, half of 930 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.